- Home
- IOVA vs NAGE Comparison
IOVA vs NAGE Comparison
Compare IOVA & NAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- NAGE
- Stock Information
- Founded
- IOVA 2007
- NAGE 1999
- Country
- IOVA United States
- NAGE United States
- Employees
- IOVA N/A
- NAGE N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- NAGE Medicinal Chemicals and Botanical Products
- Sector
- IOVA Health Care
- NAGE Health Care
- Exchange
- IOVA Nasdaq
- NAGE Nasdaq
- Market Cap
- IOVA 771.4M
- NAGE 861.0M
- IPO Year
- IOVA N/A
- NAGE N/A
- Fundamental
- Price
- IOVA $1.88
- NAGE $11.41
- Analyst Decision
- IOVA Buy
- NAGE Strong Buy
- Analyst Count
- IOVA 10
- NAGE 3
- Target Price
- IOVA $12.22
- NAGE $16.67
- AVG Volume (30 Days)
- IOVA 10.4M
- NAGE 1.0M
- Earning Date
- IOVA 08-07-2025
- NAGE 08-06-2025
- Dividend Yield
- IOVA N/A
- NAGE N/A
- EPS Growth
- IOVA N/A
- NAGE N/A
- EPS
- IOVA N/A
- NAGE 0.18
- Revenue
- IOVA $212,679,000.00
- NAGE $107,925,000.00
- Revenue This Year
- IOVA $86.62
- NAGE $26.44
- Revenue Next Year
- IOVA $69.95
- NAGE $20.06
- P/E Ratio
- IOVA N/A
- NAGE $63.14
- Revenue Growth
- IOVA 11070.12
- NAGE 29.77
- 52 Week Low
- IOVA $1.64
- NAGE $2.52
- 52 Week High
- IOVA $12.51
- NAGE $14.69
- Technical
- Relative Strength Index (RSI)
- IOVA 47.47
- NAGE N/A
- Support Level
- IOVA $1.68
- NAGE N/A
- Resistance Level
- IOVA $2.02
- NAGE N/A
- Average True Range (ATR)
- IOVA 0.11
- NAGE 0.00
- MACD
- IOVA 0.03
- NAGE 0.00
- Stochastic Oscillator
- IOVA 61.42
- NAGE 0.00
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.